UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 14, 2011
 
LANTHEUS MEDICAL IMAGING, INC.
(Exact name of registrant as specified in its charter)
 
Delaware	 	333-169785	 	51-0396366	
(State or other jurisdiction of incorporation)	 	(Commission File Number)	 	(IRS Employer Identification No.)	
 
331 Treble Cove Road, North Billerica, MA 01862
(Address of principal executive offices) (Zip code)
 
Registrant’s telephone number, including area code:  (978) 671-8001
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
Item 8.01                                            Other Events
 
Appointment of Chief Financial Officer
 
On January 14, 2011, Robert Gaffey was appointed to the position of Chief Financial Officer of Lantheus Medical Imaging, Inc. (the “Company”).  Mr. Gaffey, age 63, previously served as Vice President, Finance and Information Technology, and Treasurer, a position he held since January 2008.  In his expanded role as Chief Financial Officer, Mr. Gaffey remains the Company’s principal financial officer and will continue to serve as Treasurer.  Mr. Gaffey has held multiple positions with the Company since 1987, including Vice President Finance, Operations and General Manager Billerica Site, and Vice President Finance and Operations.  Mr. Gaffey began his career with E.I. DuPont de Nemours.  Mr. Gaffey holds a Bachelor of Science in Accounting from Bentley College and a Master of Business Administration from Widener University.
 
A copy of the Company’s press release, dated January 18, 2011, announcing the promotion of Robert Gaffey to Chief Financial Officer, is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01               Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Number	 	Description of Exhibits	
99.1	 	Press Release, dated January 18, 2011, announcing the promotion of Robert Gaffey to Chief Financial Officer	
 
2

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	LANTHEUS MEDICAL IMAGING, INC.	
 	 	
 	By:	/s/ Michael P. Duffy	
 	Name:	Michael P. Duffy	
 	Title:	Vice President and General Counsel	
 
Date:  January 18, 2011
 
3

 
EXHIBIT LIST
 
Exhibit
Number	 	Description of Exhibits	
99.1	 	Press Release, dated January 18, 2011, announcing the promotion of Robert Gaffey to Chief Financial Officer	
 
4

Exhibit 99.1

 
Contacts:	 	 	
Linda Lennox	 	Michele Rozen	
Lantheus Medical Imaging	 	Pure Communications	
Office: 978-671-8854	 	Office: 617-730-8284	
Cell: 978-995-5698	 	Cell: 617-953-2214	
 
LANTHEUS MEDICAL IMAGING ANNOUNCES PROMOTION OF ROBERT GAFFEY TO CHIEF FINANCIAL OFFICER
 
No. BILLERICA, Mass. (January 18, 2011) — Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the promotion of Robert Gaffey to Chief Financial Officer. He was most recently Vice President, Finance and Information Technology. In this expanded role, Mr. Gaffey will add the leadership for investor relations and strategic corporate communications to his current responsibilities of directing the Company’s global financial strategy. Mr. Gaffey will continue to report to Lantheus President and Chief Executive Officer, Don Kiepert.
 
“Bob has been a tremendous asset to the Company, having served in multiple leadership roles since the Company’s early days,” said Mr. Kiepert. “This promotion reflects his many contributions to the Company and the instrumental role he played in leading the Company into the public domain through our recent bond offering. As Chief Financial Officer, Bob’s financial expertise will continue to be of significant value as we execute our corporate strategy and grow the Company.”
 
Mr. Gaffey has served in several key leadership positions at the Company for more than 35 years. Starting his career when the Company was part of E.I. DuPont de Nemours, he helped lead the Company through its transition to Bristol-Myers Squibb Medical Imaging and the sale to a private equity investment firm, which re-launched the Company as Lantheus Medical Imaging.  Mr. Gaffey earned a B.S. from Bentley College and an M.B.A. from Widener University.
 
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve

 
the treatment of human disease. The Company’s proven success in discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY ®  Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR ® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite ® (Technetium Tc99m Generator), Cardiolite ®  (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 650 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
 
Safe Harbor for Forward-Looking and Cautionary Statements
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
 
###